CD24 and neoplasm: A second trial is underway to evaluate prognostic value of stem cell related markers (CD24, CD44, CD326 and EPCR) for predicting breast cancer recurrence in tumor stages 0-II, but it was withdrawn for lacking of financial support (ClinicalTrials.gov Identifier: NCT01265225).